 |
 Video: What is a Stock Split?
|
|
|
| Reviva Pharmaceuticals Holdings is a clinical-stage biopharmaceutical company. Co.'s pipeline has two drug candidates, brilaroxazine (RP5063) and RP1208. Co.'s main drug candidate, brilaroxazine, is in clinical development and is intended to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis. Furthermore, brilaroxazine is for two respiratory indications, pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Co.'s RP1208 is for the treatment of depression and obesity. According to our Reviva Pharmaceuticals Holdings stock split history records, Reviva Pharmaceuticals Holdings has had 0 splits. | |
|
Reviva Pharmaceuticals Holdings (RVPH) has 0 splits in our Reviva Pharmaceuticals Holdings stock split history database.
Looking at the Reviva Pharmaceuticals Holdings stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Reviva Pharmaceuticals Holdings shares, starting with a $10,000 purchase of RVPH, presented on a split-history-adjusted basis factoring in the complete Reviva Pharmaceuticals Holdings stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
10/19/2018 |
|
| End date: |
05/03/2024 |
|
| Start price/share: |
$9.72 |
|
| End price/share: |
$3.20 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-67.08% |
|
| Average Annual Total Return: |
-18.16% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$3,293.18 |
|
| Years: |
5.54 |
|
|
|
|
|
